• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

    5/13/25 4:05:56 PM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVOK alert in real time by email

    Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million

    Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use

    SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

    "We're pleased to report continued strong revenue growth in the first quarter of 2025," said Matt D'Onofrio, Chief Executive Officer of Evoke Pharma, Inc. "Net product sales rose 77% year-over-year, underscoring the strength of our commercial execution and GIMOTI's growing adoption. We believe the underlying demand drivers remain strong—we achieved a 73% increase in fill rate and a 44% increase in our total prescriber base compared to Q1 last year. These improvements reflect continued depth of engagement and expanding interest among healthcare providers."

    First Quarter 2025 Highlights and Recent Developments

    Corporate Governance

    • Appointed Greg Pyszczymuka to the Board of Directors. His extensive experience in commercial strategy and revenue growth will be valuable as the company advances its market position.

    Commercial Execution

    • GIMOTI demonstrated solid momentum in Q1 with strong repeat usage, increasing prescription depth, and stable conversion rates.
    • Realized a 73% year-over-year increase in fill rate, driven by expanded pharmacy partnerships and reduced fulfillment friction.
    • Grew the total prescriber base by 44%, with increased provider confidence in GIMOTI's efficacy and convenience.
    • Maintained strategic emphasis on GLP-1 patient populations, where the need for effective non-oral options continues to grow.

    First Quarter 2025 Financial Results

    For the first quarter of 2025, net product sales were approximately $3.1 million compared with $1.7 million during the first quarter of 2024, and net loss was approximately $1.3 million ($0.51 per share) compared with $1.6 million, ($2.09 per share) for the first quarter of 2024.

    For the first quarter of 2025, selling, general, and administrative expenses were approximately $4.3 million compared to $3.1 million for the first quarter of 2024. The increase was due to higher professional fees and reimbursement and profit-sharing activity with EVERSANA as a result of an increase in net product sales.

    Total operating expenses for the first quarter of 2025 were approximately $4.4 million compared to $3.2 million for the same period in 2024.

    As of March 31, 2025, cash and cash equivalents were approximately $12.6 million. We believe, based on our current operating plan, that our existing cash and cash equivalents, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the second quarter of 2026.

    2025 Outlook

    Evoke reiterates its 2025 net product sales guidance of approximately $16 million, reflecting a 60% increase over 2024. Evoke's 2025 guidance is dependent on its current business and expectations, including recent growth rates in net product sales, assumptions regarding reimbursements and prescription fills, as well as factors that are outside of our control, such as the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures.

    "We've entered 2025 with strong momentum and a clear path forward," added Mr. D'Onofrio. "With focused execution, expanded provider engagement, and the ongoing relevance of GIMOTI in a growing diabetic patient population, we're confident in our ability to continue delivering growth and impact for patients who need better treatment options."

      

    About Evoke Pharma, Inc.

    Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. We developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

    Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

    Visit www.EvokePharma.com for more information.

    Follow Evoke Pharma on LinkedIn

    Follow Evoke Pharma on Twitter

    About Gimoti® (metoclopramide) nasal spray

    GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information

    WARNING: TARDIVE DYSKINESIA

    • Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.
    • Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.
    • Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use.

    GIMOTI is not recommended for use in:

    • Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.
    • Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.

    GIMOTI is contraindicated:

    • In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.
    • When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage mechanical obstruction, or perforation).
    • In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.
    • In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.
    • In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.

    Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.

    Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    Safe Harbor Statement

    Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions.

    These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2025 net product sales; potential future provider engagement; the ongoing relevance of GIMOTI in a growing diabetic population; Evoke's commercialization plans, including underlying drivers of potential growth and seasonality in sales; and Evoke's expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke's business, including, without limitation: Evoke may not be able to achieve its guidance for 2025 including as a result of decreased demand for GIMOTI; Evoke's and EVERSANA's ability to successfully drive market demand for GIMOTI; Evoke's ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; EVERSANA may terminate the commercial services agreement and loan agreement which would require us to repay the outstanding principal and interest underlying our loan agreement with EVERSANA; Evoke's dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke's ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke's prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Investor & Media Contact:

    Daniel Kontoh-Boateng

    DKB Partners

    Tel: 862-213-1398

    [email protected]

    Evoke Pharma, Inc.
    Balance Sheets
          
     March 31,  December 31, 
     2025  2024 
     (Unaudited)    
    Assets     
    Current assets:     
    Cash and cash equivalents$12,624,090  $13,596,600 
    Accounts receivable, net of allowance for credit losses of $0 2,511,490   2,420,373 
    Prepaid expenses 523,910   731,945 
    Inventories 532,145   445,081 
    Other current assets 39,240   43,898 
    Total current assets 16,230,875   17,237,897 
    Operating lease right-of-use asset 138,758   154,184 
    Deferred offering costs —   120,614 
    Other long-term assets 6,312   6,312 
    Total assets$16,375,945  $17,519,007 
    Liabilities and stockholdersʼ equity     
    Current liabilities:     
    Accounts payable and accrued expenses$2,781,203  $2,341,191 
    Accrued compensation 371,732   865,650 
    Operating lease liability 61,625   59,533 
    Note payable 5,000,000   5,000,000 
    Accrued interest payable 2,236,953   2,113,665 
    Total current liabilities 10,451,513   10,380,039 
    Operating lease liability, net of current portion 83,217   100,958 
    Total liabilities 10,534,730   10,480,997 
    Commitments and contingencies     
    Stockholdersʼ equity:     
    Preferred stock, $0.0001 par value; authorized shares — 5,000,000 as of March 31, 2025 and December 31, 2024; issued and outstanding shares — zero as of March 31, 2025 and December 31, 2024 —   — 
    Common stock, $0.0001 par value; authorized shares — 100,000,000 and 50,000,000 as of March 31, 2025 and December 31, 2024, respectively; issued and outstanding shares — 1,492,858 and 1,486,009 as of March 31, 2025 and December 31, 2024, respectively 149   149 
    Additional paid-in capital 135,938,876   135,829,493 
    Accumulated deficit (130,097,810)  (128,791,632)
    Total stockholdersʼ equity 5,841,215   7,038,010 
    Total liabilities and stockholdersʼ equity$16,375,945  $17,519,007 
            



    Evoke Pharma, Inc.
    Statements of Operations
     
     Three Months Ended March 31, 
     2025  2024 
    Net product sales$3,080,158  $1,735,490 
    Operating expenses:     
    Cost of goods sold 41,613   92,529 
    Research and development 42,783   4,645 
    Selling, general and administrative 4,297,505   3,139,536 
    Total operating expenses 4,381,901   3,236,710 
    Loss from operations (1,301,743)  (1,501,220)
    Other income (expense):     
    Interest income 118,853   46,058 
    Interest expense (123,288)  (124,658)
    Total other expense (4,435)  (78,600)
    Net loss$(1,306,178) $(1,579,820)
    Net loss per share of common stock, basic and diluted$(0.51) $(2.09)
    Weighted-average shares used to compute basic and diluted net loss per share 2,548,684   756,808 


    Primary Logo

    Get the next $EVOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVOK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EVOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hill Malcolm R

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:28 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Brady Todd C

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:29 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Garner Cam L

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:24 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for GIMOTI

      Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

      1/15/21 5:10:35 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "We're pleased to report continued strong revenue growth in the first quarter of 2025," said Matt D'Onofrio, Chief Executive Officer of Evoke Pharma, Inc. "Net product sales rose 77% year-over-year, underscoring the strengt

      5/13/25 4:05:56 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

      SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA. The analysis leverages real-world data from over 100 million U.S. patients and highlights differences in TD incidence rates and timing based on metoclopramide dosing patterns. "This

      4/28/25 8:30:48 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatm

      3/13/25 4:02:27 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    SEC Filings

    See more
    • Evoke Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Evoke Pharma Inc (0001403708) (Filer)

      5/22/25 4:30:21 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Evoke Pharma Inc.

      SCHEDULE 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      5/15/25 3:51:53 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Evoke Pharma Inc.

      10-Q - Evoke Pharma Inc (0001403708) (Filer)

      5/13/25 4:20:20 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Financials

    Live finance-specific insights

    See more
    • Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatm

      3/13/25 4:02:27 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

      SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes. Management will host a conference call and webcast with accompanying slides on Thursday, March 13, 2025, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 267-6316 and (203) 518-9783 for international callers. The conference ID number is EVOKQ424.

      3/6/25 8:30:28 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

      GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription fill increase; 39% increase since Q1 2024 Real-world data presented at ACG 2024 demonstrates that GIMOTI significantly enhanced outcomes for patients on GLP-1 therapy, marking it as a promising supportive care option compared to oral metoclopramide. SOLANA BEACH, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (met

      11/7/24 4:05:52 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Leadership Updates

    Live Leadership Updates

    See more
    • Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

      SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke's commercial strategy and growth potential. Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commer

      2/24/25 8:30:37 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

      SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company's Board of Directors effective October 18, 2024.   This appointment fulfills a condition set as part of the company's most recent financing by Nantahala Capital Management. Mr. Smeal brings extensive experience in investment management and corporate governance. Before transitioning to full-time private investing, he held roles at Willett Advisors, the family office of Michael R. Bl

      10/22/24 8:30:15 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

      SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D'Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer's departure for personal reasons. Mr. D'Onofrio currently serves as President and Chief Operating Officer. "Working closely with Dave has been an absolute privilege," said Matt D'Onofrio, incoming Chief Executive Officer of Evoke Pharma. "His relentless leadership resulted in our company developing and launchi

      3/21/24 4:15:59 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evoke Pharma Inc.

      SC 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      11/14/24 1:08:23 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evoke Pharma Inc.

      SC 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      11/14/24 9:19:50 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Evoke Pharma Inc.

      SC 13D/A - Evoke Pharma Inc (0001403708) (Subject)

      11/6/24 4:31:54 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care